THU081 Differences In Circulating Microrna Levels In Genetically Confirmed Multiple Endocrine Neoplasia Type 1 And Multiple Endocrine Neoplasia Type 1 Phenocopies As Assessed By Next Generation Sequencing

Abstract

Abstract Disclosure: D.A. Trukhina: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). E.O. Mamedova: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). P.A. Koshkin: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). A.G. Nikitin: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). G.A. Melnichenko: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). Z.E. Belaya: Grant Recipient; Self; Russian Science Foundation (project N 19-15-00398-П). Multiple endocrine neoplasia type 1 (MEN1) is a rare disease caused by mutations in the MEN1 gene encoding the menin protein (gMEN1). This syndrome is characterized by the occurrence of parathyroid tumors, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pituitary adenomas, as well as other endocrine and non-endocrine tumors. Patients with MEN1 phenotype without MEN1 mutations are considered MEN1 phenocopies (phMEN1). It has not been studied whether the development of MEN1 phenocopies is determined by epigenetic changes, particularly by altered microRNA expression, which can affect menin. Materials & methods Single-center, case-control study: assessment of plasma microRNA expression in patients with gMEN1, phMEN1 and healthy controls. Morning plasma samples were collected from fasting patients and gender-matched controls and stored at –80C. Total RNA isolation was performed using miRNeasy Mini Kit with QIAcube. The libraries were prepared by the QIAseq miRNA Library Kit. Circulating miRNA sequencing was performed on Illumina NextSeq 500. Subsequent data processing was performed using DESeq2 bioinformatics algorithm. Results We enrolled 24 patients with gMEN1 and 12 patients with phMEN1, along with 12 gender-matched controls. The median age of gMEN1 patients was 39 [35; 46]; in phMEN1 — 59 [51;60]; control — 59 [51.5; 62.5]. The gMEN1 group differed in age (p<0,01) compared to phMEN1 and control groups. We divided all assessed microRNAs into 3 groups based on the significance of the results: the first group consisted of samples with the highest level of detected microRNAs (>50 counts), the second group — moderate (10–50), the third group — the lowest (<10).98 microRNAs were differently expressed in groups gMEN1 and phMEN1 (84 upregulated microRNAs, 14 — downregulated). We found increased expression of microRNAs in gMEN1 which interact with menin: hsa-miR-421 (p adj = 0.0004362), hsa-miR-664a-5p (p adj = 0.0037814). We found several microRNAs associated with intestinal and pituitary tumors in gMEN1 and phMEN1 groups: up-regulated hsa-miR-7-5p (p adj = 0.0000084); downregulated hsa-miR-423-5p (p adj < 0.000001) and hsa-miR-432-5p (p adj = 0.0087227). 84 microRNA were differently expressed in groups gMEN1 and control (67 up-regulated microRNAs, 17 — downregulated). When comparing gMEN1 with phMEN1 and control a decrease in hsa-let-7a-5p miRNA was found, which, according to the literature, is downregulated in Men1 gene knockout cell lines. The phMEN1 vs control group showed downregulation of hsa-miR-122-5p (p adj = 0.0080138) and upregulation of hsa-miR-191-5p (p adj = 0.0002144), hsa-miR-486-5p (p adj = 0.0491822) that has been detected in GEP-NETs. Conclusion We found microRNAs which could potentially become biomarkers in the differential diagnosis of gMEN1 and phMEN1. The results need to be validated using a different measurement method with a larger sample size. Presentation: Thursday, June 15, 2023